Peptron Inc - Asset Resilience Ratio
Peptron Inc (087010) has an Asset Resilience Ratio of 57.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Peptron Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Peptron Inc's Asset Resilience Ratio has changed over time. See 087010 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Peptron Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Peptron Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩105.49 Billion | 57.41% |
| Total Liquid Assets | ₩105.49 Billion | 57.41% |
Asset Resilience Insights
- Very High Liquidity: Peptron Inc maintains exceptional liquid asset reserves at 57.41% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Peptron Inc Industry Peers by Asset Resilience Ratio
Compare Peptron Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
|
Purple Biotech Ltd
TA:KTOV |
Biotechnology & Medical Research | 0.01% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
Annual Asset Resilience Ratio for Peptron Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Peptron Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 72.74% | ₩122.85 Billion ≈ $83.25 Million |
₩168.89 Billion ≈ $114.46 Million |
+71.37pp |
| 2023-12-31 | 1.37% | ₩718.34 Million ≈ $486.81K |
₩52.50 Billion ≈ $35.58 Million |
-23.89pp |
| 2022-12-31 | 25.26% | ₩17.24 Billion ≈ $11.69 Million |
₩68.27 Billion ≈ $46.27 Million |
-13.57pp |
| 2021-12-31 | 38.83% | ₩30.24 Billion ≈ $20.49 Million |
₩77.87 Billion ≈ $52.77 Million |
-21.15pp |
| 2020-12-31 | 59.98% | ₩70.59 Billion ≈ $47.84 Million |
₩117.70 Billion ≈ $79.76 Million |
+31.21pp |
| 2019-12-31 | 28.77% | ₩17.55 Billion ≈ $11.89 Million |
₩60.99 Billion ≈ $41.33 Million |
-8.57pp |
| 2018-12-31 | 37.34% | ₩26.80 Billion ≈ $18.16 Million |
₩71.76 Billion ≈ $48.63 Million |
+6.92pp |
| 2017-12-31 | 30.42% | ₩16.14 Billion ≈ $10.94 Million |
₩53.05 Billion ≈ $35.95 Million |
-31.32pp |
| 2016-12-31 | 61.75% | ₩35.75 Billion ≈ $24.23 Million |
₩57.90 Billion ≈ $39.24 Million |
+61.31pp |
| 2015-12-31 | 0.43% | ₩94.00 Million ≈ $63.70K |
₩21.66 Billion ≈ $14.68 Million |
-0.38pp |
| 2014-12-31 | 0.81% | ₩94.00 Million ≈ $63.70K |
₩11.58 Billion ≈ $7.84 Million |
-- |
About Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more